Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Neurol. 2024 Mar;271(3):1072-1079. doi: 10.1007/s00415-023-12128-9. Epub 2023 Dec 23.
The objective of this study was to investigate the factors influencing relapse and prognosis in patients with primary autoimmune cerebellar ataxia (PACA), an area previously not well understood.
This prospective cohort study included patients who satisfied the modified diagnostic criteria of PACA. A modified Rankin scale score ≤ 2 at the last follow-up was defined as a favorable prognosis. Cox and Logistic regression were utilized to identify relapsing and prognostic factors, respectively.
A total of 68 patients were included and 35.3% were male. The median onset age was 42.9 years (IQR 22.1-54.0). Neuronal autoantibodies were detected in 33 (50.8%) patients. Of the 65 patients who received first-line immunotherapy, 55 (84.6%) were responsive and 10 (15.4%) were not. Responsiveness to first-line immunotherapy emerged as an independent factor for favorable prognosis (HR 16.762; 95% CI 2.877-97.655; p = 0.002), as did the absence of peripheral neuropathy/radiculopathy (HR 14.286; 95% CI 2.41-83.333; p = 0.003). Relapses occurred in 19 (27.9%) patients. Onset age ≤ 43 years (HR 5.245; 95% CI 1.499-18.35; p = 0.009), presence of peripheral neuropathy/radiculopathy (HR 4.280; 95% CI 1.622-11.298; p = 0.003) and elevated cerebrospinal fluid (CSF) protein concentration (HR 3.443; 95% CI 1.083-10.951; p = 0.036) were statistically significant relapsing factors.
This study identified younger onset age, presence of peripheral neuropathy/radiculopathy and elevated CSF protein concentration as relapsing factors, and absence of peripheral neuropathy/radiculopathy and responsiveness to first-line immunotherapy as independent factors for favorable prognosis in PACA patients. These findings may guide individualized treatment strategies and potentially improve patient outcomes.
本研究旨在探讨原发性自身免疫性小脑共济失调(PACA)患者复发和预后的影响因素,这是一个以前尚未充分了解的领域。
本前瞻性队列研究纳入符合 PACA 改良诊断标准的患者。末次随访时改良 Rankin 量表评分≤2 定义为预后良好。采用 Cox 和 Logistic 回归分别识别复发和预后因素。
共纳入 68 例患者,其中 35.3%为男性。中位发病年龄为 42.9 岁(IQR 22.1-54.0)。33 例(50.8%)患者检测到神经元自身抗体。在 65 例接受一线免疫治疗的患者中,55 例(84.6%)有反应,10 例(15.4%)无反应。一线免疫治疗有反应是预后良好的独立因素(HR 16.762;95%CI 2.877-97.655;p=0.002),无周围神经病/神经根病也是预后良好的独立因素(HR 14.286;95%CI 2.41-83.333;p=0.003)。19 例(27.9%)患者复发。发病年龄≤43 岁(HR 5.245;95%CI 1.499-18.35;p=0.009)、存在周围神经病/神经根病(HR 4.280;95%CI 1.622-11.298;p=0.003)和脑脊液(CSF)蛋白浓度升高(HR 3.443;95%CI 1.083-10.951;p=0.036)是统计学上显著的复发因素。
本研究确定了发病年龄较小、存在周围神经病/神经根病和 CSF 蛋白浓度升高是复发的因素,而不存在周围神经病/神经根病和对一线免疫治疗有反应是 PACA 患者预后良好的独立因素。这些发现可能指导个体化治疗策略,并有可能改善患者的预后。